Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight

Abstract
It has been known since the first identified SARS epidemic that the receptor critical for SARS-CoV entry into host cells is the angiotensin-converting enzyme 2 (ACE2), an important actor on renin-a...
Funding Information
  • CNPq
  • Research Foundation for the State of Piauí—FAPEPI